S. Waqar

发表

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

V. Rusch, Bruce E. Johnson, I. Wistuba, 2019, Journal of Clinical Oncology.

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

M. Kris, V. Rusch, Bruce E. Johnson, 2018 .

Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)

J. Neal, H. Wakelee, C. Liang, 2016 .

Treatment advances in small cell lung cancer (SCLC)

D. Morgensztern, S. Waqar, 2017, Pharmacology & therapeutics.

Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer.

G. Colditz, S. Broderick, T. Crabtree, 2015, The Annals of thoracic surgery.

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer

J. Bradley, C. Robinson, M. Roach, 2020, Journal of thoracic disease.

Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?

G. Colditz, S. Broderick, T. Crabtree, 2016, The Journal of thoracic and cardiovascular surgery.

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

Alex H. Wagner, Zachary L. Skidmore, R. Wilson, 2018, Nature Communications.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer

J. Subramanian, R. Govindan, K. Trinkaus, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small Cell Lung Cancer, Version 2.2022

P. Iyengar, B. Loo, A. Chiang, 2021 .

Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.

M. Mix, J. Bogart, S. Waqar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

H. Wakelee, J. Nieva, T. Shaffer, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY

M. Kris, M. Socinski, J. Soria, 2014 .

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

S. Gulati, Yeon-Hee Park, A. Italiano, 2020, The Lancet. Oncology.

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

M. Socinski, R. Herbst, F. Hirsch, 2018 .

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germlineBRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, S. Im, 2019, Poster Discussion Abstracts.

Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

Immune checkpoint inhibition in patients with brain metastases.

D. Morgensztern, T. Johanns, S. Waqar, 2016, Annals of translational medicine.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

M. Kris, V. Rusch, I. Wistuba, 2021 .

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

M. Kris, V. Rusch, I. Wistuba, 2022, Nature Medicine.

Immunogenicity of Influenza Vaccination in Patients With Cancer

F. Gao, R. Govindan, D. Morgensztern, 2015, American journal of clinical oncology.

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

L. Sequist, J. Nemunaitis, E. Juhász, 2014, Journal of Immunotherapy for Cancer.

Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors.

F. Gao, R. Govindan, D. Morgensztern, 2022, Lung cancer.

MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)

M. Kris, V. Rusch, I. Wistuba, 2018, Journal of Thoracic Oncology.

Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.

M. Kris, M. Socinski, J. Minna, 2016 .

A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.

R. Herbst, K. Kelly, D. Gandara, 2017 .

Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on supportive care issues related to lung cancer.

R. Govindan, S. Waqar, L. Boehmer, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Influenza vaccination in patients with cancer: an overview.

R. Govindan, S. Waqar, L. Boehmer, 2010, Oncology.

Lorlatinib: a new-generation drug for ALK-positive NSCLC.

D. Morgensztern, S. Waqar, 2018, The Lancet. Oncology.

Precision medicine in lung cancer: the battle continues.

D. Morgensztern, S. Waqar, 2016, Journal of thoracic disease.

The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy.

R. Govindan, S. Waqar, 2020, JAMA oncology.

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)

Y. Bang, A. Italiano, S. Domchek, 2018 .

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

M. Kris, J. Minna, I. Wistuba, 2017, Clinical Cancer Research.

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study

D. Ettinger, M. Kris, M. Socinski, 2017 .

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients

M. Krzakowski, T. Owonikoko, J. Fujimoto, 2017, Oncotarget.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

C. Rudin, M. Kris, I. Wistuba, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).

R. Herbst, K. Kelly, D. Gandara, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

P. Jänne, R. Govindan, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

R. Govindan, K. Pepin, D. Morgensztern, 2022, Frontiers in Oncology.

Genomic Profiling of Lung Adenocarcinoma in Never-Smokers

R. Wilson, R. Fulton, L. Ding, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

R. Govindan, R. Suresh, D. Morgensztern, 2021, Journal of thoracic disease.

Clinical next‐generation sequencing in patients with non–small cell lung cancer

Rakesh Nagarajan, John D Pfeifer, Shashikant Kulkarni, 2015, Cancer.

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

H. Beltran, A. Mansfield, C. Chung, 2021, npj Precision Oncology.

Trends in Stage I Lung Cancer.

F. Gao, R. Govindan, V. Puri, 2022, Clinical lung cancer.

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Jeffrey Bradley, Feng Gao, R. Govindan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

J. Berlin, Hulin Jin, C. Robinson, 2022, Investigational New Drugs.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

C. Rudin, R. Govindan, A. Chaudhuri, 2019, Clinical Cancer Research.

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

L. Schwartz, R. Herbst, F. Hirsch, 2020, Clinical lung cancer.

A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer.

R. Govindan, J. Bradley, B. Goodgame, 2014, Clinical lung cancer.

Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

G. Colditz, R. Govindan, J. Bradley, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A roundup of articles published in recent months.

J. Subramanian, R. Govindan, D. Morgensztern, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer

R. Govindan, D. Morgensztern, S. Waqar, 2016, Chemotherapy.

Targeted Therapy in Solid Tumors: Lung Cancer

R. Herbst, D. Morgensztern, S. Waqar, 2015 .

Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005

J. Subramanian, R. Govindan, D. Morgensztern, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted Therapy in Lung Cancer: Lessons Learned from Past Experiences

J. Subramanian, R. Govindan, S. Waqar, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.

J. Crowley, J. Villano, K. Chansky, 2020, Clinical lung cancer.

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

F. Gao, C. Liang, L. Ratner, 2022, Cancer Chemotherapy and Pharmacology.

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

David J. Sims, J. Foster, R. Simon, 2021, JCO precision oncology.

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors

R. Govindan, B. V. Van Tine, A. Lockhart, 2020, Cancer Chemotherapy and Pharmacology.

Association between depth of response and survival in patients with advanced‐stage non–small cell lung cancer treated with first‐line chemotherapy

M. Socinski, P. Postmus, D. Morgensztern, 2019, Cancer.

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

J. Trepel, P. Ma, D. Morgensztern, 2019, British Journal of Cancer.

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

A. Italiano, S. Domchek, Young-Ae Park, 2019, Annals of Oncology.

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

A. Shaw, R. Doebele, K. Davies, 2018, Clinical Cancer Research.

Systemic Treatment of Brain Metastases.

R. Govindan, D. Morgensztern, S. Waqar, 2017, Hematology/oncology clinics of North America.

Recent Advances in Lung Cancer: Summary of Presentations from the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011

J. Subramanian, R. Govindan, D. Morgensztern, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Delayed nausea and vomiting from carboplatin doublet chemotherapy

R. Govindan, D. Morgensztern, S. Waqar, 2016, Acta oncologica.

Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non–Small Cell Lung Cancer

R. Govindan, V. Puri, D. Morgensztern, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer

P. Jänne, K. Yoh, S. Modi, 2018, Journal of Thoracic Oncology.

Multimodality Therapy for NSCLC.

D. Morgensztern, S. Waqar, L. Du, 2016, Cancer treatment and research.

Non–small‐cell Lung Cancer With Brain Metastasis at Presentation

R. Govindan, J. Bradley, V. Puri, 2018, Clinical lung cancer.

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

J. Neal, H. Wakelee, C. Liang, 2018, Clinical Cancer Research.

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

P. Iyengar, B. Loo, A. Chiang, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

A Placebo‐Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First‐Line Treatment of Patients With Advanced Nonsquamous Non–Small‐Cell Lung Cancer and Systemic Inflammation

G. Giaccone, G. Kennealey, A. Martínez-Martí, 2018, Clinical Lung Cancer.

Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials

R. Govindan, D. Morgensztern, S. Waqar, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA03.08 Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI): Topic: Medical Oncology

H. Wakelee, C. Liang, L. Gandhi, 2017 .

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

M. Kris, V. Rusch, I. Wistuba, 2021 .

FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies

P. Jänne, M. Burkard, D. Solit, 2021 .

P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial

M. Kris, V. Rusch, I. Wistuba, 2019, Journal of Thoracic Oncology.

A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.

R. Herbst, S. Ramalingam, P. Baas, 2014 .

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003

Kathryn Trinkaus, Janakiraman Subramanian, Feng Gao, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538

J. Bradley, R. Komaki, L. Gaspar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.

G. Colditz, T. Crabtree, D. Kreisel, 2015, The Annals of thoracic surgery.

436PDPreliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors

H. Beltran, F. Kaye, A. Mansfield, 2017 .

Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?

D. Morgensztern, S. Waqar, 2015, Expert review of clinical immunology.

Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer.

R. Govindan, J. Bradley, D. Morgensztern, 2022, International journal of radiation oncology, biology, physics.

Trajectories of participation in daily life among individuals newly diagnosed with cancer: A 5-month longitudinal study

Yan Yan, Yikyung Park, M. Chheda, 2023, Supportive Care in Cancer.

FP07.13 Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer

R. Govindan, D. Morgensztern, J. Ward, 2021 .

P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib

J. Neal, H. Wakelee, C. Liang, 2019, Journal of Thoracic Oncology.

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.

H. Beltran, A. Mansfield, C. Chung, 2020 .

Circulating cell-free tumor DNA (cfDNA) testing in small cell lung cancer.

R. Govindan, D. Morgensztern, R. Lanman, 2016 .

Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer

D. Morgensztern, J. Jennings, A. Tomasian, 2017, CardioVascular and Interventional Radiology.

83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A

R. Herbst, K. Kelly, D. Gandara, 2017 .

MET Mutation Associated with Responsiveness to Crizotinib.

D. Morgensztern, S. Waqar, Jennifer K Sehn, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D

M. Socinski, J. Engelman, R. Herbst, 2017 .

A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).

C. Rudin, M. Kris, I. Wistuba, 2016 .

MA 07.02 Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients

J. Neal, H. Wakelee, J. Nieva, 2017 .

88OCNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts)

J. Neal, H. Wakelee, S. Patel, 2017 .

P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK

J. Neal, H. Wakelee, C. Liang, 2016 .

Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?

G. Colditz, S. Broderick, T. Crabtree, 2015, The Annals of thoracic surgery.